Copenhagen
-
Still Hungry for New Obesity Meds, Novo Nordisk Makes Another M&A Deal
Novo Nordisk is expanding its cardiometabolic drug pipeline with the acquisition of Embark Biotech, a startup developing drugs for a novel target that can suppress appetite and boost calorie burning in cells. Embark’s science comes University of Copenhagen research on a novel fat cell target.
-
Blood Clotting Biotech Hemab Hauls In $135M to Drug Rare Bleeding Disorders
Hemab Therapeutics will apply its Series B financing toward clinical development of its lead drug candidate, a potential treatment for Glanzmann thrombasthenia. The capital will also support the rest its pipeline addressing rare bleeding and thrombotic diseases with no approved therapies.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Biologics manufacturing drives Evotec’s $435M U.S. stock market debut
Evotec is an old player in the life sciences, but in offering new shares on the Nasdaq, the Germany-based company plans to bolster its new biologics manufacturing capabilities in the U.S and Europe. In other stock market debuts, IO Biotech’s IPO raised $100 million as it prepares a pivotal test of its lead cancer immunotherapy.
-
Seagen, Genmab antibody drug conjugate gets FDA approval in cervical cancer
The Seagen and Genmab antibody drug conjugate (ADC), named Tivdak, is approved to treat cases of cervical cancer that have returned or spread following treatment with chemotherapy. Tivdak is Seagen’s third ADC; for Genmab, the drug will become its first commercialized product.
-
FDA rejection of rare disease drug leads Orphazyme to cut two thirds of staff
Orphazyme’s corporate restructuring comes less than two weeks after the FDA rejected arimoclomol, a drug developed to treat the rare Niemann-Pick disease type C. The company said it is now focused on securing regulatory approval in Europe and finding a path forward for the small molecule with the FDA.
-
Two new biotechs unveil $112M combined for antibody drug conjugates for cancer
The list of FDA-approved antibody drug conjugates (ADC) is growing, and two more biotech startups have emerged from stealth with new cash and new approaches to this type of cancer drug. Adcendo and Adcentrx raised a combined $112 from their Series A financings.
-
AbbVie, Denmark’s Genmab enter nearly $4B cancer immunotherapy partnership
The deal, which includes a hefty $750 million upfront payment to Genmab, focuses on bispecific antibodies and also a drug discovery research partnership.
-
FDA approves first monkeypox vaccine, which also protects against smallpox
The agency announced the approval of Bavarian Nordic’s Jynneos. A 2003 outbreak in the Midwest marked the first time monkeypox was found outside of its native Africa. Smallpox has been eradicated, but bioterrorism concerns remain.
-
Denmark’s Genmab files for $500M Nasdaq listing in US
The company, whose FDA-approved products include the myeloma drug Darzalex and the chronic leukemia drug Arzerra, hopes to launch its own proprietary product by 2025.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Devices & Diagnostics, Startups
LEO Pharma launches new innovation lab with $65M in funding for non-pharmaceutical dermatology expansion
LEO Pharma, which has had a primary focus on skin conditions like psoriasis, has launched its new Innovation Lab to further explore treatment options that don’t involve medication.
-
As pharma looks for leaner models, Novo Nordisk expected to spin out IT business this week
It’s no secret that big pharma has been getting leaner, with companies buying and selling […]
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
